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Abstract
The transfer of foreign genes into mammalian cells has been essential for understanding the functions of genes and
mechanisms of genetic diseases, for the production of coding proteins and for gene therapy applications. Currently, the
identification and selection of cells that have received transferred genetic material can be accomplished by methods,
including drug selection, reporter enzyme detection and GFP imaging. These methods may confer antibiotic resistance, or
be disruptive, or require special equipment. In this study, we labeled genetically modified cells with a cell surface
biotinylation tag by co-transfecting cells with BirA, a biotin ligase. The modified cells can be quickly isolated for downstream
applications using a simple streptavidin bead method. This system can also be used to screen cells expressing two sets of
genes from separate vectors.
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Introduction
The transfer of foreign genes into eukaryotic cells, and in
particular, into mammalian cells, plays an important role in our
understanding of the function of coding genes and the regulatory
components of non-coding sequences and also allows the
production of coding proteins for therapeutic purposes and the
development of strategies for gene therapy [1]. The rapid
identification and selection of gene-modified cells are prerequisites
for these applications.
Several systems have been developed for the selection of cells
after gene transfer, including drug selection, GFP imaging and
detectionof otherreporters [2,3,4,5].Antibiotic selection isthe most
commonly used method and is based on the growth advantage of
the transfectants in the presence of a cytotoxic agent along with the
death of the non-transduced cells. The widely-used antibiotic
resistance genes include aminoglycoside phosphotransferase, dihy-
drofolate reductase (DHFR), hygromycin B phosphotransferase,
puromycin-N-acetyl-transferase, blasticidin S deaminase, and
glutamine synthetase (GS), which confer resistance to G418,
methotrexate, hygromycin, puromycin, blasticidin, and methionine
sulfoximine respectively [6,7,8,9,10,11]. Isolation of gene-modified
cells usingthis method requires severaldaysto weeks andintroduces
undesirable drug resistance genes into the cells. Identification of
transfected cells using reporter genes such as chloramphenicol
acetyltransferase, alkaline phosphatase, b-galactosidase and firefly
luciferase typically requires disruptive methods like cell permeabi-
lization [7,9,12]. Green fluorescent protein (GFP) can be detected
without cell permeabilization and is useful in fluorescence-activated
cell sorting applications, but it can be toxic to cells.
Magnetic-activated cell sorting (MACS) is a simple solution for
applications requiring the enrichment of cells of interest. MACS is
dependent on the expression of a specific surface marker that can
be recognized by a magnetic bead-tagged antibody. Gotoh et al.
described eight streptavidin fusion genes as dominant selectable
markers that can be combined with paramagnetic beads to select
transfected cells [13]. Using MACS, it is possible to identify rare
cell populations, separate large number of cells and large as many
as 10
11 cells in approximately 1 hour [14]. The immunomagnetic
selection procedure is simple and rapid. This method yields a
highly pure population of transfected cells and can be used for a
wide range of biological applications. Several approaches have
been put forwarded to develop simpler and faster selection
strategies. Kawahara et al. have proposed a novel selection system
called the antigen-mediated genetically modified cell amplification
(AMEGA) system, which employs an antibody/receptor chimera
that triggers a growth signal in response to a cognate antigen
without antibiotic selection [15,16,17,18,19].
The association of Streptavidin with biotin is the strongest
known non-covalent bond, which is several orders of magnitude
stronger than that of antigen-antibody interactions. The biotin
ligase, BirA, can catalyze the biotinylation of the e-NH2 of a 13-
amino acid peptide tag, a so-called minimal biotin acceptor
sequence [20,21] and has been widely used for biotinylation of a
protein of interest. In this study, we take advantage of a biotin
ligase enzyme to catalyze the biotinylation of a cell-surface peptide
tag co-transferred into the same cell to create an efficient vector
system for modifying cells genetically.
The selection system consists of two vectors; one contains a
target gene and the biotin ligase BirA as a reporter, and the other
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to a truncated form of human low-affinity nerve growth factor
receptor (DLNGFR). The target gene cassette in each vector is
used to express the genes of interest. Once the lentivectors enter
cells through transient transfection or infection, one or more of the
target proteins are expressed. BirA is retained in the endoplasmic
reticulum (ER) after expression, and it efficiently biotinylates the
BirA tags fused to DLNGFR when they pass through the ER. The
biotinylated DLNGFR is transported to the cell surface where it
labels the target cell. The biotinylated cells have a high affinity for
streptavidin and can be quickly and efficiently captured in vitro
with streptavidin-labeled beads [22]. Using this method, highly
pure populations of transfected cells can be obtained. Late-
generation lentiviral vectors with advanced performance and
safety profiles can efficiently transduce several types of nondividing
and dividing cells. This method can be used to isolate mammalian
cells modified by two sets of target genes from heterogeneous cell
pools using magnetic streptavidin-labeled beads. This system has
been used in multiple cell types, including the 293T, HCT-15,
SupT1 and K42-91a, a mouse fibroblast cell line.
Results
1. Cell surface expression of BirA enzyme substrate linked
to a truncated LNGFR
To express a biotinylated tag on the cell surface, we constructed
a tag protein composed of an ER leader sequence and a biotin tag
peptide, the biotinylation of which can be catalyzed by co-
expressed BirA, and a transmembrane protein fragment with a
built-in Myc tag. Initially, both the HLA-A2 transmembrane
protein and a truncated form of LNGFR were tested, and LNGFR
was found to express the tag protein more efficiently [23].
Therefore, a truncated form of LNGFR containing the trans-
membrane domain and cytoplasmic tail was used as a fusion
partner for the expression of the BirA substrate at the cell surface.
As depicted in Fig. 1A, two lentivectors were constructed. Vector 1
contained a CMV promoter-driven transgene expression cassette
and an EF-1alpha promoter-driven truncated LNGFR tagged
with the BirA substrate peptide reporter. Vector 2 contained a
second transgene cassette and the BirA enzyme to catalyze the
biotinylation of the BirA peptide tag at the cell surface when co-
expressed with the BirA substrate peptide in Vector 1. To test the
vector system, a GFP reporter gene was inserted into the transgene
expression cassette of Vector 1, termed 3.7lnGFP, and a
lentivector containing the BirA expression cassette without a
transgene was created and named 3.7CMVBirA. Both lentiviruses
were produced in 293T cells using standard procedures.
To confirm that a biotinylated peptide tag was expressed on the
cell surface, 293T cells were first transfected with the two
lentiviruses, 3.7lnGFP and 3.7CMVBirA. The surface expression
of biotinylated LNGFP was confirmed by binding to streptavidin-
labeled beads 72 hours after transfection. As shown in Fig. 1B,
cells expressing the biotinylated tag could be isolated with
streptavidin-labeled beads, and almost all of the cells bound to
the beads expressed GFP, this is further confirmed by FACS
quantification (Fig. 2B). The surface expression of DLNGFR and
Myc was also verified by FACS. As shown in Fig. 2A, cells
transfected with 3.7lnGFP and cells transfected with both
3.7lnGFP and 3.7CMVBirA were stained with either anti-Myc
or anti-LNGFR antibodies. The positive percentage stained with
anti-Myc was 76.18% (3.7lnGFP) and 64.46% (both 3.7lnGFP
and 3.7CMVBirA ) respectively, while the ones stained with anti-
LNGFR was 69.38% (3.7lnGFP) and 66.15% (both 3.7lnGFP and
3.7CMVBirA) respectively. The cells transfected with
3.7CMVBirA alone were not stained by both antibodies above
the background level of 7.33% and 6.99% respectively. Histogram
analysis of flow cytometry data showed a broad range of staining
intensity of non-isolated cells; however, the cells isolated with
streptavidin-labeled beads formed a distinct population, the
positive percentage being 98.05% (anti-Myc) and 97.07% (anti-
LNGFR). The percentage of GFP positive cells is 68% (3.7lnGFP)
or 70.16% (both 3.7lnGFP and 3.7CMVBirA) individually, and
the percentage of streptavidin positive cells was 62.94%. Almost
87% GFP positive cells could be stained with streptavidin (Fig. 2B).
In the following experiments, western blots were performed to
confirm whether biotinylation occured only when both BirA and
the BirA substrate peptide tag were expressed by the same cell. As
shown in Fig. 3A, cells that expressed the BirA substrate peptide
tag alone or in combination with BirA could be stained with either
anti-Myc or anti-LNGFR antibodies. In contrast, only cells
expressing both proteins were stained with streptavidin, indicating
that biotinylation took place only when both proteins were
expressed in the same cell. FACS analysis (Fig. 3B) strengthened
the results as 93.86% cells expressed biotinylated proteins on the
surface of cells.
2. Isolation of the gene-modified cell lines with
streptavidin-labeled magnetic beads
In the next set of experiments, the efficient isolation of clones
containing transgenes was demonstrated. As shown in Fig. 4A,
293T clones that expressed GFP were quickly established by
infection and sorting with magnetic beads. The 293T cells were
first infected with 3.7lnGFP and 3.7CMVBirA lentiviruses. After
infection, the GFP-expressing 293T cells were isolated using
streptavidin-labeled beads. Only GFP-positive cells adhered to the
streptavidin-labeled beads. Single 293T cells isolated with
streptavidin-labeled beads were further cultured, and single cell-
derived clones were established within a period of a few days.
Similarly, HCT-15 clones expressing GFP were established by
infection and magnetic bead sorting. After infection with
3.7lnGFP and 3.7CMVBirA, GFP-positive HCT-15 cells were
isolated with streptavidin-labeled beads, and a clone was
established in one week (Fig. 4B). Long term and stable expression
of transgene was investigated by FACS analysis of GFP expression,
the percentage of GFP-positive cells at day 20 was 98%, and 88%
GFP positive cells can be stained with streptavidin (Fig. 4D).
One application for this system is the expression of biotinylated
proteins in established 293T cells expressing the BirA enzyme. To
establish a 293T cell line stably expressing the BirA enzyme, 293T
cells were first infected with 3.7CMVBirA lentivirus. Next, the
same cells were transiently transfected with 3.7lnGFP vector, and
the modified cells were isolated with streptavidin-labeled magnetic
beads (Fig. 4C).
3. HCT-15 cells modified with a single transgene (b2m-
gp100) were specifically targeted by TCR-modified NK
cells
To further demonstrate the efficiency of transgenic cell
isolation, we transduced HCT-15 cells with b2m linked to a
peptide derived from gp100 (b2m-gp100). HCT-15 cells are b2m-
deficient human colorectal cancer cell line. Because they lack b2m,
no stable HLA I molecules are expressed at the cell surface. As
shown in Fig. 5B, non-transduced HCT-15 cells did not express
HLA class I molecules at the surface. HCT-15 cells were infected
with two lentiviral vectors: one expressing b2m-gp100 and the
BirA substrate peptide tag and another expressing the BirA
enzyme. Biotinylated cells were isolated with magnetic streptavi-
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presence of b2m on the surface of HCT-15 cells was confirmed by
FACS analysis using W6/32 or BBM.1 antibodies, wherein
approximately 92.22% (BBM.1) and 95.18% (W6/32) of trans-
duced cells were stained (Fig. 5B, top and middle panels).
Biotinylated proteins at the cell surface were detected with
streptavidin-PE-Cy5, and observed staining in approximately
87.13% of transduced cells (Fig. 5B, bottom panels). We further
tested the stability of b2m/gp100 expression in HCT-15 cells
using FACS analysis. 20
th passage of established b2m/gp100-
positive HCT-15 cells were stained with mAb W6/32 ( Fig. 5D) of
which 92.64% were positive.
The established b2m/gp100-positive HCT-15 cells were further
tested as target cells for NK92MI cells expressing GPA7A, a T cell
receptor (TCR)-like antibody specific for a gp100 peptide-loaded
HLA-A2 complex. As shown in Fig. 5C, the established b2m/
gp100-positive HCT-15 cells were effectively targeted by GPA7A-
transfected NK92MI cells, which specifically recognized target cells
expressing the gp100 peptide-loaded HLA-A2complex.In contrast,
parental NK92MI cells induced a much lower level of cytotoxicity.
4. The establishment of cell lines expressing two sets of
desired transgenes
The potential of this system was further realized by the efficient
establishment of cells modified with two sets of transgenes. The
individual genes were cloned into separate lentiviral vectors and
introduced into target cells, and stably transduced cell lines were
then isolated. Two pairs of genes, a combination of human b2m
and HLA-A2 and the combination of melanoma associated-Ag
gp100-specific TCR-alpha and -beta chains, were used to establish
the cell lines. The K42-91a cell line [24], a variant of the K42
mouse fibroblast cell line in which TAP2 has been knocked down
with a targeted knockout of the CRT gene, was used to establish
gene-modified cells expressing the HLA class I complex.
Lentiviruses expressing HLA-A2 and human b2m were used to
infect K42-91a cells, the cells modified with both HLA-A2 and
b2m were isolated using magnetic streptavidin-labeled beads, and
stable clones were established. Staining with anti-HLA complex
antibodies showed that human HLA I complexes were expressed
on the surface of murine k42-91a cells (Fig. 6A, top two panels),
the cells were also stained with anti-Myc antibody and
Figure 1. Isolation of genetically-modified cell lines with streptavidin-labeled magnetic beads. (A) Schematic structures of the
lentivectors used for delivery of the genes of interest into cells. 3.7EF-1a-ER-DLNGFR-CMV-transgene was a lentivector derived from the backbone of
pll3.7. The first transgene is expressed in a cassette with an CMV promoter. A truncated form of the membrane-anchored human low-affinity nerve
growth factor receptor (LNGFR) tagged with BirA tag (GLNDIFEAQKIEWHE) peptide was driven by a EF-1a promoter in a separate cassette. 3.7EF-1a-
transgene-CMV-ER-BirA was a lentivector containing the second transgene expression cassette and the BirA enzyme as a reporter gene. (B) The 293T
cells were co-transfected with 3.7lnGFP and 3.7CMVBirA lentivectors and isolated with streptavidin-labeled magnetic beads. Merged images (left
panels), GFP fluorescence images (right panels).
doi:10.1371/journal.pone.0026380.g001
Selection of Gene-Modified Cell
PLoS ONE | www.plosone.org 3 November 2011 | Volume 6 | Issue 11 | e26380streptavidin-PE-cy5 (Fig. 6A, bottom two panels). The surface
expression of the human HLA I complex on k42-91a cells was
further confirmed by flow cytometry, which showed a shift to the
right in the human HLA I staining profile. In contrast, the staining
profile of an irrelevant peptide did not change (Fig. 6B). To
confirm stable expression of HLA-A2 and human b2m in K42-91a
cells, 15
th passage of established HLA-A2 and b2m transduced
K42-91a cells were analyzed using FACS ( Fig. 6C).
In another set of experiments, SupT1 cells were modified to
express TCR genes. Wild-type SupT1 cells are TCR-deficient,
and although all of the genes for the CD3 components are present,
these cells do not express surface CD3 because of the lack of the
TCR. The TCR is composed of alpha and beta chains and is
MHC restricted. The CD3 complex is expressed on the surface of
SupT1 cell when both of the TCR subunits are re-expressed. The
TCR-alpha and -beta chains derived from melanoma-specific T
cells were inserted into the transgene expression cassettes of the
respective lentivectors, and viruses expressing the transgenes were
produced [25]. SupT1 cells were infected with both a virus
containing the TCR-alpha gene and a virus containing the TCR-
beta gene. After isolation with magnetic streptavidin-labeled
beads, the cells were further cultured, and the expression of the
modified genes was confirmed by FACS analysis. As presented in
Fig. 6D, CD3, LNGFR, TCR-alpha and -beta chains and
biotinylated transmembrane proteins were clearly expressed on
SupT1 cells due to the integration of both the TCR-alpha and -
Figure 2. FACS analysis of genetically-modified cell lines. (A) FACS staining of transfected 293T cells with antibodies against the marker
proteins LNGFR and Myc. 293T Cells were transfected with 3.7lnGFP, 3.7CMVBirA, or both 3.7lnGFP and 3.7CMVBirA and selected with streptavidin-
labeled beads. The cells were then analyzed by flow cytometry to detect the level of surface expression of Myc or LNGFR. Histogtams indicate Myc
and LNGFR expression (top four panels, middle four panals), shaded histograms represented untransfected 293T cells. The percentage of positive
cells is indicated in each panel. (B) Flow cytometric analysis of coexpression of GFP and biotinylated DLNGFR. The cells were stained with
streptavidin-PE-Cy5. GFP and streptavidin double positive cells are indicated by gate and percentage. Shown are the data represented as a dot-plot
analysis of stained tansfected 293T cells.
doi:10.1371/journal.pone.0026380.g002
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cells expressing TCR were obtained after infection (Fig. 6D, left
panels) and magnetic bead separation (Fig. 6D, right panels).
Discussion
The development of cell-based gene therapy and the production
of recombinant proteins for clinical applications both require
genetically modified cells. These applications are largely hampered
by the lack of protocols for the simple isolation of genetically
modified cells. In this report, we have described a new method that
permits the specific and efficient isolation of gene-modified cells
based on the strong and specific interaction between biotin and
avidin [13]. In our system, mammalian cells are modified with two
separate vectors, one expressing the BirA enzyme, which has been
engineered to be retained in the endoplasmic reticulum (ER), and
the other expressing as a transmembrane protein with a BirA
substrate peptide tag [26,27,28,29,30,31,32,33,34]. The BirA
substrate peptide tag will be expressed on the surface of a cell
when both genes are expressed along with two sets of target genes.
The resulting biotin-labeled cells can be isolated using magnetic
streptavidin-labeled beads. In this way, genetically modified cells
can be obtained as early as 72 hours post-infection. The viability
of the cell lines is not affected, and there is no toxic effect on cell
proliferation [35,36,37].
Gene therapy depends on both efficient gene transfer into the
appropriate target cells and the ability to enrich the transduced
cells. Conventional selectable markers have limitations, including
growth inhibition, mutations in antibiotic resistance genes, cell
membrane permeability and morphological changes. DLNGFR is
a truncated native receptor that is not immunogenic, does not
mediate signal transduction and is already being used in clinical
protocols [38]. DLNGFR is easily tracked in vivo, and cells
expressing this transgene can be isolated using magnetic or
fluorescence-activated cell sorting. The BirA enzyme is a foreign
protein introduced into the cells and is designed as an ER-resident
protein [22]. Although no cytotoxic effects have been reported
upon introduction of BirA into cells, its potential effects on cell
cycle and its long-term safety require further investigation [28].
The human immunodeficiency virus type-1(HIV-1) based
lentiviral vectors provide high and stable transgene in both
dividing and non-dividing cell types, the third generation self-
inactivating (SIN) vectors minimize the risk of reconstituting a
replication-competent lentivirus (RCL). In our lentiviral system,
two ubiquitously internal promoters in lentivectors, human
elongation factor-1a (EF-1a) promoter [39,40] and cytomegalo-
virus (CMV) promoter [35,41], were chosen to drive transgene
expression, and stable cell lines were generated in different cell
types. We also tested whether transgene expression could be stably
maintained when transduced cells are expanded where we
Figure 3. Expression and biotinylation of the transmembrane protein ER-DLNGFR. (A) Western blot analysis of the expression and
biotinylation of the transmembrane protein ER-DLNGFR. 293T cells were transfected with 3.7lnGFP lentivector alone or in combination with
3.7CMVBirA lentivector. Forty-eight hours after transfection, the transfected cells and control untransfected 293T cells were lysed in SDS sample
buffer, and the samples were separated on 10% SDS-PAGE gels and transferred to blotting membranes. The blots were probed with anti-Myc or anti-
LNGFR (CD271) antibodies and streptavidin-labeled HRP and visualized by ECL. lane 1, 3.7lnGFP transfected 293T; lane 2, untransfected 293T; lane 3,
3.7lnGFP and 3.7CMVBirA cotransfected 293T. (B) FACS analysis of a biotinylated transmembrane protein. HCT-15 cells were infected with both
3.7lnGFP and 3.7CMVBirA lentivirus (black line ) or with 3.7lnGFP alone as a negative control (shaded histogram). The infected cells were stained with
streptavidin-PE and analyzed using a flow cytometer.
doi:10.1371/journal.pone.0026380.g003
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passages in different cell types. However, silencing of vector
transgene is an important factor to consider where long term stable
expression of transgene is required in target cells. There are
specific reports stating many transgenes driven by viral promoter
including the CMV promoter have been found gradually silenced
over period of months in certain cell types [42]. Replacement of
CMV promoter by appropriate cell-type specific promoters when
needed facilitate efficient transgene manipulation and isolation of
gene-transducted cells.
Our results show that the use of this selective system allows for
rapid, efficient, and nontoxic in vitro selection of gene-modified
cell. This system has been applied in many different cell lines and
will provide an option in isolating tranfected cells, and set to use
the system to select the TCR-alpha and -beta genes derived from
melanoma-specific T cells transduced human primary T cells
which has future prospects to treat melanoma. More importantly,
the selective system can be used to design vaccine, owing to gene-
modified DC vaccine expressing TAA, gene encoding cytotoxic T
lymphocyte (CTL)-specific epitopes, and are promising vaccine
candidates to be utilized for treatment of cancer [43,44,45], In
summary, this methodology provides many potential of applica-
tion in adoptive gene therapy, producing recombinant protein and
studying the function of genes.
Materials and Methods
Lentiviral Vector construct
We used the backbone of the pLL3.7 plasmid (Invitrogen,
Carlsbad, CA, USA) (Fig. 1A) to construct the 3.7transgene 1BirA
and 3.7lntransgene 2 lentivectors, termed 3.7BirA and 3.7ln,
respectively (Fig. 1). To obtained EF-1a-ER-DLNGFR fragment,
the DLNGFR sequence was amplified from the template
pPRIME-CMV-LNGFR-cloning vector( PMID 16141338) using
primer: LN-PstI, 59 GCATGGACTGCAGGAACAAAAACT-
CATCTCAGAAGAGGA 39; LN-1,59 CAT CTCAGAAGAG-
GATCTGGGA GGTGCATGCCCCACAGGCCT 39 and LN-
NotI, 59 GATAAGAATGCGGCCGCTCTAGAACTAGT 39,
was cloned into PEF/Myc/ER vector (Invitrogen, USA), and
then the EF-1a-ER-DLNGFR was inserted into XbaI and NotIo f
pll3.7 plasmid to get 3.7EF-1a-ER-DLNGFR-CMV-GFP
(3.7lnGFP) which u6 promoter–driven siRNAs expressing cassette
was replaced. GFP gene can be replaced with foreign transgenes.
The BirA enzyme gene was amplified by PCR from the POZ-BirA
plasmid(previously constructed in our lab), The primers used to
Figure 4. The efficient establishment of genetically-modified clones. (A) 293T clones expressing GFP were rapidly established by infection
and sorting with magnetic beads. The 293T cells were first lentivirally transduced with 3.7lnGFP and 3.7CMVBirA. After infection, 293T cells expressing
GFP were dissociated with 0.5 mM EDTA and mixed with streptavidin-labeled beads. Only GFP-positive cells adhered to the streptavidin-labeled
beads. Single 293T cells isolated with the streptavidin-labeled beads were cultured to form a stable cell line within ten days. (B) HCT-15 clones
expressing GFP were established by infection and sorted with magnetic beads. HCT-15 cells were infected with 3.7lnGFP and 3.7CMVBirA. After
infection, the GFP-positive HCT-15 cells were isolated with streptavidin-labeled beads. (C) Establishment of a 293T cell line stably expressing BirA.
293T cells were first infected with 3.7CMVBirA lentivirus, then transiently transfected with 3.7lnGFP vector and mixed with streptavidin-labeled beads.
The modified cells were isolated using streptavidin-labeled magnetic beads. (D) Stable expression of transgene in HCT-15 cells. After 20 days of
selection, the stable expression of GFP was determined by FACS analysis. Shown are the data represented as a dot-plot analysis.
doi:10.1371/journal.pone.0026380.g004
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TAACACCGTGCC ACTGAA and BirA-NotI, AAGGAAA-
AAAGCGGCCGCGTTTTTTGCACTAC GCAGGG. The am-
plified fragment was ligated into the SalI and NotI sites of the PEF/
Myc/ER vector. The stop codon of BirA was deleted to introduce
an ER retention signal at the C terminus of BirA, termed ER-birA.
Next, the ER-BirA gene was subcloned by digesting PEF/myc/
ER-BirA with NheI and EcoRI and inserting the fragment
containing ER-BirA into the pll3.7 lentiviral vector. For expression
of a single transgene, the GFP or b2m-gp100 (a gp100 epitope-
linked hb2m sequence ) gene was cloned into the 3.7ln vector at
the NheI and EcoRI sites. For expression of two transgenes, the
TCR-alpha and -beta chain genes, HLA-A2, as well as the human
b2m genes were cloned into the 3.7ln and 3.7BirA vectors
respectively. The SphI and BamHI sites were used for cloning into
the 3.7BirA vector. The primers used to amplify gp100-TCR from
APB plasmid (a gift from Dr. Richard Morgan) were as follows:
TCR-A-PmlI(+), 59 GTCACG TGGCCA CCATGGTGAA-
GATCCGGCAA 39; TCR-A-BamHI(2), 59 CGCGGATCCT-
CAGCTGGACCACAGCCGCA39; TCR-B-NheI(+), 59CTA-
GCTAGCCACCATGGACT CCTGGACCTTC TGCTG39;
and TCR –B –EcoRI( 2)5 9CCGGAATTCTCATCCCCTTCT-
TCTGAGAC39. The primers b2m-NheI-h, 59ATCGGCTAGCA-
TGTCTCGCTCCGTGGCCTT39 and b2m -MunI-h, 59 ATG-
Figure 5. HCT-15 cells modified with a single transgene (b2m-gp100) were specifically targeted by TCR-modified NK cells. (A)
Modified HCT-15 cells were isolated with streptavidin-labeled beads, and single cell-derived clones were grown for 8 days. (B) FACS analysis of HCT-
15 cells transduced with 3.7ln b2mgp100 and 3.7cmvBirA lentivirus. The cells were stained with mAbs W6/32, which is specific for HLA-A, B and C,
BBM1, which is specific for b2m and streptavidin-PE-Cy5 conjugate. Mock-infected HCT-15 cells were infected with lentivirus without a target gene
(shaded histograms). HCT-15 cells were infected with lentivirus 3.7ln b2mgp100 and 3.7CMVBirA (left panels) and selected by streptavidin-labeled
beads (right panels). (C) Specific killing of HCT-15 cells expressing b2mgp100 by NK92MI/gp100 cells. NK92MI-pef-GPA7A is a NK92MI cell line
expressing GPA7A, a TCR-like antibody specific for HLA-A2 loaded with gp100 peptide. The parental NK92MI cell line was used as a control. The
results are presented as percentage 6SD from five individual experiments. (D) Stable expression of b2mgp100 gene in lentivirus transduced HCT-15
cells. Transduced cells were passed 20 passages and stained with W6/32 antibody (black line). Mock-transduced HCT-15 served as a negative control
(shaded histogram).
doi:10.1371/journal.pone.0026380.g005
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amplify human b2m. We then used the primers, A2-SphI, 59
ATGCATGCGCCACCATGGCCGTCAT GGC G 39 and A2-
BamHI, 59 CGCGGATCCTCACACTTTACAAGCTGTGA-
GAG 39 to generate the HLA-A 2 chains. Both hb2m and
HLA-A 2 genes were amplified from pCDNA3.1A2B2 plasmid
(previously constructed in our lab).
Cell lines and antibodies
The HEK293T cells and the HCT-15 colon adenocarcinoma cells
used in this study were cultured in Dulbecco’s modified Eagle medium
(DMEM) supplemented with 10% fetal bovine serum (Gibco BRL,
C a i t h e r s b u r g ,M D ,U S A ) .T h eTl y m p h o i dS u p T 1 ,N K 9 2 M Ia n d
K42-91a cell lines were cultured in RPMI-1640 medium supplement-
ed with 10% fetal bovine serum (FBS) and 100 U/mL penicillin/
streptomycin. All cell lines were purchased from ATCC (Rockville,
MD, USA) except HCT-15 cells (a gift from Chen Au Phe) and K42-
91a cell line [24]. All transformants were supplemented with biotin at a
final concentration of 100 mM. Cells were maintained in 5% CO2 in a
37uC incubator. W6/32, BBM.1, anti-Myc, mouse anti-Human
CD271 (anti-LNGFR), anti-human-CD3-FITC and anti-human-
TCR-a/b-PE antibodies were obtained from MACS (Miltenyi Biotec,
Cologne, Germany). Anti-mouse-IgG-PE-Cy5, HRP conjugated goat
anti-mouse IgG and anti-mouse-IgG-FITC antibodies were obtained
from Sigma-Aldrich (St Louis, Mo, USA). Streptavidin-PE-Cy5
conjugate and streptavidin-PE conjugate were purchased from
eBiosicence (San Diego, CA, USA). HRP-conjugated streptavidin
was from BD PharMingen (San Diego, CA, USA).
Figure 6. Efficient establishment of double transgenic cell lines. (A) HLA-A2 and b2m gene expression in the K42-91a cell line. K42-91a cells
transduced with HLA-A2 and b2m were stained for transgene expression with anti-Myc antibody and streptavidin-PE-Cy5, and the expression of HLA-I
molecules was determined using the mAbs W6/32 and BBM1. Mock-transduced K42-91a served as a negative control (shaded histogram). (B) Cell
lines expressing both HLA-A2 and b2m (shaded histogram) were loaded with an HLA-A2-restricted peptide epitope derived from the melanoma
protein Mart1 (black line) using an HLA-B27 peptide as a control (grey line). (C) Stable expression of HLA-A2 and b2m in K42-91a cells. Transduced
cells were passed 15 passages and stained with W6/32 antibody (black line). Mock-transduced K42-91a served as a negative control (shaded
histogram). (D) Establishment of T cell lines expressing TCR genes. TCRa and TCRb genes specific for the gp100 peptide were transduced into SupT1
cells using two lentiviruses. Transduced SupT1 cells were isolated with streptavidin-labeled beads. The established SupT1 cells were stained with anti-
human TCRa/b, anti-human CD3, and anti-LNGFR antibodies or streptavidin-PE-Cy5 conjugate. Left panels: before isolation, right panels: after
isolation. Mock transduced-SupT1 cells served as a negative control (shaded histogram).
doi:10.1371/journal.pone.0026380.g006
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transduction and selection of transfected cells
VSV-G pseudotyped lentiviral vectors stocks were prepared,
concentrated, and titered as described previously [46]. Briefly,
293T cells were transiently transfected with 6 mg of packaging
plasmids pLP1, pLP2 and pLP/VSVG (Invitrogen, Carlsbad, CA,
USA) respectively and 6 mg of transfer vector. After 48 hours,
virus-containing supernatants were harvested, passed through a
0.45 mm filter and frozen in aliquots at 280uC until used. The
virus was used to transduce different cell lines in the presence of
4 mg/mL polybrene at different the multiplicity of infection (MOI).
Adherent cells (293T, HCT-15, K42-91a) were transduced at an
MOI of 1, suspension cells (supT1) were transduced at an MOI of
20. All cells were transduced by spin inoculation in a centrifuge at
1,8006 g for 90 minutes at 32uC in 6-well tissue culture plates
(2 mL per well) and incubated at 37uC overnight; fresh medium
was added after the overnight incubation. This process was
repeated once after every 24 hours later. A mock infection (no
vector-containing medium) was always performed in parallel
under identical culture conditions. Magnetic bead-based cell
separation was performed 72 hours post-infection. After the
lentiviral infection and separation of transduced cell lines, the
transduction efficiency was monitored by flow cytometry.
Magnetic bead-based cell separation
To avoid potential cleavage of surface proteins by trypsin, the
adherent cells were released from the plates with 0.5 mM EDTA.
The cell suspension was washed 3 times to remove unbound d-
biotin. Next, Dynabead M-280 streptavidin-labeled beads (In-
vitrogen, Carlsbad, CA,USA) were mixed with the cell suspension
at a ratio of 10 ml bead suspension per 1 mL (1610
7) target cell
suspension. The resulting mixture was rotated for 20 minutes on
ice. The tubes were placed into a magnetic device for 5 minutes,
and the bound cells were collected. Tubes were removed from the
magnet, and the beads were washed once with phosphate-buffered
saline (PBS) / 2% FBS. The collected cells were harvested and
resuspended in 1.5 mL PBS (pH 7.4). These procedures were
repeated three or four times. The biotin-positive cells were
separated from the suspension with a magnetic unit. The presence
of the biotinylated surface marker on the harvested cells was
confirmed either by additional staining of the cells with antibody
or by observation of GFP in unstained cells under a fluorescence
microscope.
SDS-PAGE and western blotting
One million cells were lysed and centrifuged, and the
supernatants were boiled in SDS sample buffer for 5 minutes
and separated by SDS-PAGE in a 12% polyacrylamide gel.
The proteins in the gel were then transferred to Hybond C
Extra membrane (Amersham) at 20 V for 2 hours. The
membrane was blocked in 10 mL of PBS containing 2%
Marvel milk (Premier International Foods, St Albans, UK) on
a plate rocker (Stuart Gyro Rocker STR-9) for 1 hour and
transferred to 10 mL of Phosphate Buffered Saline with Tween
20 (PBST) /2% Marvel milk containing a 1:1500 dilution of
the primary antibody. The membrane was washed 3 times and
transferred to PBST/2% Marvel milk containing a 1:5000
dilution of the HRP-conjugated secondary antibody. The
membrane was washed twice in PBST and twice in PBS and
dabbed dry with a paper towel. Two milliliters of enhanced
chemiluminescence fluid were added evenly to the membrane.
After 5 minutes, the fluid was pipetted off, and the membrane
was dabbed dry which was then wrapped in Parafilm and
attached to one side of an exposure box with tape.
Photographic film (Kodak Biomax) was exposed to the
membrane for 10 seconds to 30 minutes.
Flow cytometry analysis
W6.32, BBM.1, anti-LNGFR and anti-Myc were used as
primary antibodies. The cells were washed 3 times with PBS, and
1610
6 cells were incubated with mAbs on ice for 30 minutes and
then incubated with or without secondary antibody (mouse IgG
conjugated to FITC or PE-Cy5). The anti-human-TCR-a/b-PE
antibody was used according to the manufacturer’s instructions.
After each incubation, the cells were washed twice with PBS. The
labeled cells were analyzed by flow cytometry with a Guava
Easycyte (Guava Technologies, Hayward, CA, USA). All FACS
data were analyzed using FlowJo software (Tree Star, Ashland,
OR, USA).
Cytotoxicity assay
Target cells were washed twice with Hank’s buffered salt
solution (HBSS) before staining. The 1–2610
7 cells were then
incubated for 10 min with Hank’s buffered salt solution (HBSS)
supplemented with 2 mM carboxyfluorescein succinimidyl ester
(CFSE, Invitrogen, Merelbeke, Belgium) at 37uC in the dark.
Immediately following the addition of the CSFE, an equal volume
of FBS was added to stop the reaction. After incubation with FBS
for 1 min, the target cells were washed twice with HBSS and
resuspended in complete medium at a concentration of 1610
5
cells /mL; 100 ml of each sample was added to each well of a 96-
well U-bottom plate. Triplicate samples containing mixtures of
effector and target cells at E:T ratios of 1:1, 2:1, 4:1, 8:1, 16:1, and
32:1 were prepared. The cells were incubated at 37uC for 4 hours
in the presence of 5% CO2. After incubation, the cells were
transferred to a 1.5 mL tube, centrifuged at 2506g for 5 minutes,
washed once with ice-cold medium and resuspended in 500 ml ice-
cold medium. The cells were incubated for 3 minutes on ice with
10 mg/mL propidium iodide ( PI; Sigma-Aldrich, Poole, England)
and both green and red fluorescence were analyzed. Cells stained
with both dyes represent dead target cells. Analysis was on gated
CFSE positive cells only. The percentage of cytotoxic activity was
calculated using the following formula: %specific death=(%total
CFS
+PI
+ (dead) cells2%spontaneous CFSE
+PI
+ (dead) cells)/
(100%2%spontaneous CFSE
+PI
+ (dead)cells)6100%. The per-
centage of spontaneous dead cells was measured in the tube
containing target cells only [47].
Image Acquisition
Images were acquired on a ZEISS Axiovert 200 M microscope
(Zeiss, Vienna, A) with a 406NA 0.55 objective. The microscope
and image acquisition were controlled by Axiovision software. For
GFP observation we used the blue light excitation. Image
processing, such as clipping of images, image montages etc. was
performed in PowerPoint.
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